Literature DB >> 30108993

Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core.

Mohamed Salah1, Mohammad Abdel-Halim2, Matthias Engel1.   

Abstract

We present the development of conformationally pre-organised Dyrk1A inhibitors based on the hydroxybenzothiazole urea scaffold. The modifications introduced to the discovered hit (AHS-211) proved the crucial role of the urea linker to preserve the bioactive conformation and led to the development of compound b5 as a promising selective Dyrk1A inhibitor.

Entities:  

Year:  2018        PMID: 30108993      PMCID: PMC6071757          DOI: 10.1039/c8md00142a

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  19 in total

1.  Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules.

Authors:  Ulli Rothweiler; Wenche Stensen; Bjørn Olav Brandsdal; Johan Isaksson; Frederick Alan Leeson; Richard Alan Engh; John S Mjøen Svendsen
Journal:  J Med Chem       Date:  2016-10-21       Impact factor: 7.446

Review 2.  Activation, regulation, and inhibition of DYRK1A.

Authors:  Walter Becker; Wolfgang Sippl
Journal:  FEBS J       Date:  2010-12-03       Impact factor: 5.542

3.  Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors.

Authors:  Gregory D Cuny; Maxime Robin; Natalia P Ulyanova; Debasis Patnaik; Valerie Pique; Gilles Casano; Ji-Feng Liu; Xiangjie Lin; Jun Xian; Marcie A Glicksman; Ross L Stein; Jonathan M G Higgins
Journal:  Bioorg Med Chem Lett       Date:  2010-06-15       Impact factor: 2.823

4.  The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.

Authors:  Ryo Kimura; Kouzin Kamino; Mitsuko Yamamoto; Aidaralieva Nuripa; Tomoyuki Kida; Hiroaki Kazui; Ryota Hashimoto; Toshihisa Tanaka; Takashi Kudo; Hidehisa Yamagata; Yasuharu Tabara; Tetsuro Miki; Hiroyasu Akatsu; Kenji Kosaka; Eishi Funakoshi; Kouhei Nishitomi; Gaku Sakaguchi; Akira Kato; Hideyuki Hattori; Takeshi Uema; Masatoshi Takeda
Journal:  Hum Mol Genet       Date:  2006-11-29       Impact factor: 6.150

5.  Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins.

Authors:  Ahmed K ElHady; Mohammad Abdel-Halim; Ashraf H Abadi; Matthias Engel
Journal:  J Med Chem       Date:  2017-05-31       Impact factor: 7.446

6.  Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome.

Authors:  Fei Liu; Zhihou Liang; Jerzy Wegiel; Yu-Wen Hwang; Khalid Iqbal; Inge Grundke-Iqbal; Narayan Ramakrishna; Cheng-Xin Gong
Journal:  FASEB J       Date:  2008-05-28       Impact factor: 5.191

7.  Manipulation of alternative splicing by a newly developed inhibitor of Clks.

Authors:  Michiko Muraki; Bisei Ohkawara; Takamitsu Hosoya; Hiroshi Onogi; Jun Koizumi; Tomonobu Koizumi; Kengo Sumi; Jun-ichiro Yomoda; Michael V Murray; Hiroshi Kimura; Kiyoshi Furuichi; Hiroshi Shibuya; Adrian R Krainer; Masaaki Suzuki; Masatoshi Hagiwara
Journal:  J Biol Chem       Date:  2004-03-08       Impact factor: 5.157

8.  Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases.

Authors:  W Becker; Y Weber; K Wetzel; K Eirmbter; F J Tejedor; H G Joost
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

9.  Phosphorylation of β-Tubulin by the Down Syndrome Kinase, Minibrain/DYRK1a, Regulates Microtubule Dynamics and Dendrite Morphogenesis.

Authors:  Kassandra M Ori-McKenney; Richard J McKenney; Hector H Huang; Tun Li; Shan Meltzer; Lily Yeh Jan; Ronald D Vale; Arun P Wiita; Yuh Nung Jan
Journal:  Neuron       Date:  2016-04-21       Impact factor: 17.173

Review 10.  Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control.

Authors:  Walter Becker
Journal:  Cell Cycle       Date:  2012-08-23       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.